Where does PLUR stock trade?

Pluri Inc. (PLUR) is listed on NASDAQ.

What sector and industry is PLUR in?

Pluri Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.

What companies are similar to PLUR?

Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare PLUR side-by-side with any of them on Quantisnow.

How can I track PLUR on Quantisnow?

Quantisnow aggregates Pluri Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PLUR to receive live email and push alerts on every new disclosure.

PLUR

NASDAQ

Pluri Inc.

SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)

$1.86+0.06 (+3.33%)

News25/Ratings0

Price$1.86-1.52 (-44.97%)

2026-04-142026-07-17

News · 26 weeks18+67%

2026-01-252026-07-19

Mix1390d

SEC Filings7(54%)
Other3(23%)
Insider3(23%)

Latest news

25 items

5dSEC
Pluri Inc. filed SEC Form 8-K: Other Events
8-K - Pluri Inc. (0001158780) (Filer)
5dPR
Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
HAIFA, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today provided an update on the cumulative investment and ownership position of its Chairman, Mr. Alejandro Weinstein. Over the past year, Mr. Weinstein has invested more than $17 million in Pluri through a series of investments, including a $1.25 million advance investment made in June 2026 pursuant to an Advance Subscription Agreement, as disclosed in the Company’s Form 8-K filed on June 22, 2026. Mr. Weinstein currently owns more than 30% of the Company’s issued and outstanding shares. His growing com
6dSEC
Pluri Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - Pluri Inc. (0001158780) (Filer)
12dINSIDER
New insider Shorrer Doron claimed ownership of 13,628 shares (SEC Form 3)
3 - Pluri Inc. (0001158780) (Issuer)
18dINSIDER
Director Manieu Alexandre Weinstein was granted 641 shares, increasing direct ownership by 10% to 6,925 units (SEC Form 4)
4 - Pluri Inc. (0001158780) (Issuer)
27dSEC
Pluri Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
8-K - Pluri Inc. (0001158780) (Filer)
47dPR
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
Two regenerative aesthetic and longevity products, with clinically validated ingredients, are expected to reach the U.S. market during 2026, entering a rapidly expanding U.S. medical aesthetics market, projected to reach $90 billion by 2030 HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, Cellav Health and Aesthetics Ltd. ("Cellav"), has completed the development and U.S. cosmetic product listings of two flag
48dSEC
Pluri Inc. filed SEC Form 8-K: Other Events
8-K - Pluri Inc. (0001158780) (Filer)
66dSEC
SEC Form 10-Q filed by Pluri Inc.
10-Q - Pluri Inc. (0001158780) (Filer)
76dINSIDER
Director Manieu Alexandre Weinstein was granted 625,000 shares (SEC Form 4)
4 - Pluri Inc. (0001158780) (Issuer)
79dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Pluri Inc.
SCHEDULE 13D/A - Pluri Inc. (0001158780) (Subject)
87dSEC
SEC Form DEFA14A filed by Pluri Inc.
DEFA14A - Pluri Inc. (0001158780) (Filer)
87dSEC
SEC Form DEF 14A filed by Pluri Inc.
DEF 14A - Pluri Inc. (0001158780) (Filer)
114dSEC
Pluri Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
8-K - Pluri Inc. (0001158780) (Filer)
115dPR
Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement
HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri" or the "Company") (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity beneficially owned by Alejandro Weinstein, Chairman of the Board and one of the Company's largest shareholders, has entered into a Securities Purchase Agreement with Pluri for an additional $2.5 million investment in the Company at a 30% premium to the market price on March 24, 2026. This additional investment follows Mr. Weinstein's prior $2.5 million investment announced in connection with his appointment as Chairman of the Board, and further
139dSEC
Pluri Inc. filed SEC Form 8-K: Other Events
8-K - Pluri Inc. (0001158780) (Filer)
151dPR
Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent
Expands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific Enables scalable, automated manufacturing of diverse immune cell therapies using proprietary 3D expansion technology Strengthens positioning in China's growing cell therapy market and supports cross-border partnerships HAIFA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri", the "Company", "we", "our" or "us") (Nasdaq and TASE: PLUR ), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announces that the China National Intellectual Property Administration (CNIPA) has gra
157dSEC
SEC Form 10-Q filed by Pluri Inc.
10-Q - Pluri Inc. (0001158780) (Filer)
178dSEC
Pluri Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - Pluri Inc. (0001158780) (Filer)
178dPR
Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials
HAIFA, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Pluri, Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE: PLUR), a biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced the completion of the first phase of its program with Resbiomed Technologies OOD ("Resbiomed"), a European biotechnology company developing extracellular-matrix-based biomaterials and biologics for regenerative medicine. The program is being executed through Pluri's contract development and manufacturing division, PluriCDMO™. In June 2025, Pluri Biotech Ltd., a wholly owned subsidiary of the Company, and a provider of Contrac
195dINSIDER
Director Manieu Alexandre Weinstein was granted 625,000 shares (SEC Form 4)
4 - Pluri Inc. (0001158780) (Issuer)
209dPR
Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. ("Remedy Cell"), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions. Under the ongoing collaboration Remedy Cell's personnel, along with Pluri's Contract Development and Manufacturing Organization ("CDMO") division (PluriCDMO™), have successfully completed the full imp
222dSEC
Pluri Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Other Events, Financial Statements and Exhibits
8-K - Pluri Inc. (0001158780) (Filer)
222dPR
Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment
Weinstein brings a global track record of transforming companies through value unlocking, and participation in over 20 M&A transactions and more than $5 billion in exits across healthcare, biotechnology, and nutrition.Weinstein's ownership is expected to increase to approximately 30% on an issued and outstanding basis, reflecting his conviction in Pluri's asset base, its valuation potential, and its long term strategy. HAIFA, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri" or the "Company") (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that Mr. Alejandro Weinstein, one of the C
223dINSIDER
Director Manieu Alexandre Weinstein was granted 519 shares, increasing direct ownership by 5% to 10,769 units (SEC Form 4)
4 - Pluri Inc. (0001158780) (Issuer)

PLUR FAQ

4 questions

Where does PLUR stock trade?
Pluri Inc. (PLUR) is listed on NASDAQ.
What sector and industry is PLUR in?
Pluri Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
What companies are similar to PLUR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare PLUR side-by-side with any of them on Quantisnow.
How can I track PLUR on Quantisnow?
Quantisnow aggregates Pluri Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PLUR to receive live email and push alerts on every new disclosure.